Does the media favor ALLO or BCRX?

In the previous week, BioCryst Pharmaceuticals had 3 more articles in the media than Allogene Therapeutics. MarketBeat recorded 6 mentions for BioCryst Pharmaceuticals and 3 mentions for Allogene Therapeutics. BioCryst Pharmaceuticals' average media sentiment score of 0.23 beat Allogene Therapeutics' score of 0.00 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allogene Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioCryst Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to AUPH or ALLO?

In the previous week, Aurinia Pharmaceuticals and Aurinia Pharmaceuticals both had 3 articles in the media. Aurinia Pharmaceuticals' average media sentiment score of 0.20 beat Allogene Therapeutics' score of 0.00 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurinia Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Allogene Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ADMA or ALLO?

In the previous week, ADMA Biologics and ADMA Biologics both had 3 articles in the media. ADMA Biologics' average media sentiment score of 0.59 beat Allogene Therapeutics' score of 0.00 indicating that ADMA Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Allogene Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ALLO or PHVS more profitable?

Allogene Therapeutics' return on equity of -50.04% beat Pharvaris' return on equity. Company Net Margins Return on Equity Return on Assets Allogene Therapeutics N/A -50.04% -36.74% Pharvaris N/A -61.40% -56.00%

Does the media favor ALLO or PHVS?

In the previous week, Pharvaris had 13 more articles in the media than Allogene Therapeutics. MarketBeat recorded 16 mentions for Pharvaris and 3 mentions for Allogene Therapeutics. Pharvaris' average media sentiment score of 0.27 beat Allogene Therapeutics' score of 0.00 indicating that Pharvaris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allogene Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pharvaris 2 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better earnings & valuation, ALLO or VCEL?

Vericel has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Allogene Therapeutics $20K 25,220.77 -$190.89M -$0.67 N/A Vericel $306.30M 6.70 $16.52M $0.47 85.32

Does the media favor ALLO or VCEL?

In the previous week, Allogene Therapeutics had 1 more articles in the media than Vericel. MarketBeat recorded 3 mentions for Allogene Therapeutics and 2 mentions for Vericel. Vericel's average media sentiment score of 0.99 beat Allogene Therapeutics' score of 0.00 indicating that Vericel is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allogene Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vericel 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Allogene Therapeutics (ALLO) Competitors

$1.46 +0.06 (+4.29%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.48 +0.02 (+1.44%)

As of 10/9/2026 07:59 PM Eastern

Compare

ALLO vs. BCRX, AUPH, ADMA, PHVS, and VCEL

Should you buy Allogene Therapeutics stock or one of its competitors? Allogene Therapeutics's main competitors and comparable companies include BioCryst Pharmaceuticals (BCRX), Aurinia Pharmaceuticals (AUPH), ADMA Biologics (ADMA), Pharvaris (PHVS), and Vericel (VCEL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Allogene Therapeutics compare to BioCryst Pharmaceuticals?

Allogene Therapeutics (NASDAQ:ALLO) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

In the previous week, BioCryst Pharmaceuticals had 3 more articles in the media than Allogene Therapeutics. MarketBeat recorded 6 mentions for BioCryst Pharmaceuticals and 3 mentions for Allogene Therapeutics. BioCryst Pharmaceuticals' average media sentiment score of 0.23 beat Allogene Therapeutics' score of 0.00 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allogene Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioCryst Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Allogene Therapeutics has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -40.90%. Allogene Therapeutics' return on equity of -50.04% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-50.04%	-36.74%
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%

Allogene Therapeutics has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market.

BioCryst Pharmaceuticals has higher revenue and earnings than Allogene Therapeutics. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	25,220.77	-$190.89M	-$0.67	N/A
BioCryst Pharmaceuticals	$874.84M	2.50	$263.86M	-$1.50	N/A

83.6% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 13.2% of Allogene Therapeutics shares are held by company insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Allogene Therapeutics currently has a consensus target price of $8.30, suggesting a potential upside of 468.49%. BioCryst Pharmaceuticals has a consensus target price of $20.50, suggesting a potential upside of 139.77%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Allogene Therapeutics is more favorable than BioCryst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79
BioCryst Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Allogene Therapeutics beats BioCryst Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Allogene Therapeutics compare to Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Allogene Therapeutics (NASDAQ:ALLO) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Aurinia Pharmaceuticals has a beta of 1.6, indicating that its stock price is 60% more volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market.

Aurinia Pharmaceuticals has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$283.05M	7.83	$287.20M	$2.29	7.27
Allogene Therapeutics	$20K	25,220.77	-$190.89M	-$0.67	N/A

36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are held by insiders. Comparatively, 13.2% of Allogene Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Aurinia Pharmaceuticals and Aurinia Pharmaceuticals both had 3 articles in the media. Aurinia Pharmaceuticals' average media sentiment score of 0.20 beat Allogene Therapeutics' score of 0.00 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurinia Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Allogene Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aurinia Pharmaceuticals currently has a consensus target price of $17.67, suggesting a potential upside of 6.11%. Allogene Therapeutics has a consensus target price of $8.30, suggesting a potential upside of 468.49%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Allogene Therapeutics is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79

Aurinia Pharmaceuticals has a net margin of 100.84% compared to Allogene Therapeutics' net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 26.11% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%
Allogene Therapeutics	N/A	-50.04%	-36.74%

Summary

Aurinia Pharmaceuticals beats Allogene Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Allogene Therapeutics compare to ADMA Biologics?

ADMA Biologics (NASDAQ:ADMA) and Allogene Therapeutics (NASDAQ:ALLO) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

ADMA Biologics presently has a consensus price target of $18.67, indicating a potential upside of 80.18%. Allogene Therapeutics has a consensus price target of $8.30, indicating a potential upside of 468.49%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Allogene Therapeutics is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79

75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are owned by institutional investors. 3.9% of ADMA Biologics shares are owned by company insiders. Comparatively, 13.2% of Allogene Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, ADMA Biologics and ADMA Biologics both had 3 articles in the media. ADMA Biologics' average media sentiment score of 0.59 beat Allogene Therapeutics' score of 0.00 indicating that ADMA Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Allogene Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ADMA Biologics has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market.

ADMA Biologics has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$510.17M	4.55	$146.93M	$0.70	14.80
Allogene Therapeutics	$20K	25,220.77	-$190.89M	-$0.67	N/A

ADMA Biologics has a net margin of 32.98% compared to Allogene Therapeutics' net margin of 0.00%. ADMA Biologics' return on equity of 40.17% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.98%	40.17%	26.97%
Allogene Therapeutics	N/A	-50.04%	-36.74%

Summary

ADMA Biologics beats Allogene Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Allogene Therapeutics compare to Pharvaris?

Allogene Therapeutics (NASDAQ:ALLO) and Pharvaris (NASDAQ:PHVS) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

Allogene Therapeutics currently has a consensus target price of $8.30, indicating a potential upside of 468.49%. Pharvaris has a consensus target price of $58.60, indicating a potential upside of 88.42%. Given Allogene Therapeutics' higher probable upside, equities research analysts plainly believe Allogene Therapeutics is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79
Pharvaris	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Allogene Therapeutics has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	25,220.77	-$190.89M	-$0.67	N/A
Pharvaris	N/A	N/A	-$198.79M	-$3.05	N/A

In the previous week, Pharvaris had 13 more articles in the media than Allogene Therapeutics. MarketBeat recorded 16 mentions for Pharvaris and 3 mentions for Allogene Therapeutics. Pharvaris' average media sentiment score of 0.27 beat Allogene Therapeutics' score of 0.00 indicating that Pharvaris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allogene Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pharvaris	2 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

83.6% of Allogene Therapeutics shares are held by institutional investors. 13.2% of Allogene Therapeutics shares are held by company insiders. Comparatively, 11.8% of Pharvaris shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Allogene Therapeutics has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market. Comparatively, Pharvaris has a beta of -2.46, indicating that its share price is 346% less volatile than the broader market.

Allogene Therapeutics' return on equity of -50.04% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-50.04%	-36.74%
Pharvaris	N/A	-61.40%	-56.00%

Summary

Allogene Therapeutics beats Pharvaris on 11 of the 15 factors compared between the two stocks.

How does Allogene Therapeutics compare to Vericel?

Allogene Therapeutics (NASDAQ:ALLO) and Vericel (NASDAQ:VCEL) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Allogene Therapeutics has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market. Comparatively, Vericel has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market.

Allogene Therapeutics presently has a consensus target price of $8.30, indicating a potential upside of 468.49%. Vericel has a consensus target price of $58.40, indicating a potential upside of 45.64%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Allogene Therapeutics is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79
Vericel	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Vericel has a net margin of 7.91% compared to Allogene Therapeutics' net margin of 0.00%. Vericel's return on equity of 6.91% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-50.04%	-36.74%
Vericel	7.91%	6.91%	5.02%

83.6% of Allogene Therapeutics shares are held by institutional investors. 13.2% of Allogene Therapeutics shares are held by insiders. Comparatively, 7.6% of Vericel shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Vericel has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	25,220.77	-$190.89M	-$0.67	N/A
Vericel	$306.30M	6.70	$16.52M	$0.47	85.32

In the previous week, Allogene Therapeutics had 1 more articles in the media than Vericel. MarketBeat recorded 3 mentions for Allogene Therapeutics and 2 mentions for Vericel. Vericel's average media sentiment score of 0.99 beat Allogene Therapeutics' score of 0.00 indicating that Vericel is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allogene Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vericel	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vericel beats Allogene Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Allogene Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALLO vs. The Competition

Export

Metric	Allogene Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$483.69M	$3.84B	$7.16B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	16.37%
P/E Ratio	-2.18	13.42	274.15	26.16
Price / Sales	25,220.77	1,234.38	635.98	112.53
Price / Cash	N/A	116.56	76.38	53.09
Price / Book	1.12	17.17	11.21	6.34
Net Income	-$190.89M	-$22.69M	$3.50B	$381.90M
7 Day Performance	-2.67%	-1.33%	-0.90%	-1.41%
1 Month Performance	-17.05%	-8.44%	-4.44%	-3.48%
1 Year Performance	18.70%	14.02%	6.96%	1.16%

Allogene Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALLO Allogene Therapeutics	2.4432 of 5 stars	$1.46 +4.3%	$8.30 +468.5%	-3.3%	$483.69M	$20K	N/A	152	Analyst Downgrade
BCRX BioCryst Pharmaceuticals	2.9705 of 5 stars	$8.47 -1.4%	$20.40 +140.9%	+17.9%	$2.20B	$874.84M	N/A	435
AUPH Aurinia Pharmaceuticals	3.1581 of 5 stars	$16.52 +0.5%	$17.67 +6.9%	+43.3%	$2.19B	$283.05M	7.21	128	News Coverage
ADMA ADMA Biologics	4.0342 of 5 stars	$10.12 +7.9%	$18.67 +84.5%	-29.7%	$2.10B	$510.17M	14.46	647
PHVS Pharvaris	3.3601 of 5 stars	$31.91 -0.3%	$59.87 +87.6%	+36.2%	$2.09B	N/A	N/A	148	Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALLO) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Allogene Therapeutics (ALLO) Competitors

ALLO vs. BCRX, AUPH, ADMA, PHVS, and VCEL

How does Allogene Therapeutics compare to BioCryst Pharmaceuticals?

Summary

How does Allogene Therapeutics compare to Aurinia Pharmaceuticals?

Summary

How does Allogene Therapeutics compare to ADMA Biologics?

Summary

How does Allogene Therapeutics compare to Pharvaris?

Summary

How does Allogene Therapeutics compare to Vericel?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALLO vs. The Competition

Allogene Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Allogene Therapeutics (ALLO) Competitors

ALLO vs. BCRX, AUPH, ADMA, PHVS, and VCEL

How does Allogene Therapeutics compare to BioCryst Pharmaceuticals?

Does the media favor ALLO or BCRX?

Is ALLO or BCRX more profitable?

Which has more volatility and risk, ALLO or BCRX?

Which has better earnings and valuation, ALLO or BCRX?

Do insiders & institutionals hold more shares of ALLO or BCRX?

Do analysts prefer ALLO or BCRX?

Summary

How does Allogene Therapeutics compare to Aurinia Pharmaceuticals?

Which has more risk & volatility, AUPH or ALLO?

Which has better valuation & earnings, AUPH or ALLO?

Do insiders & institutionals have more ownership in AUPH or ALLO?

Does the media refer more to AUPH or ALLO?

Do analysts recommend AUPH or ALLO?

Is AUPH or ALLO more profitable?

Summary

How does Allogene Therapeutics compare to ADMA Biologics?

Do analysts prefer ADMA or ALLO?

Do insiders & institutionals hold more shares of ADMA or ALLO?

Does the media refer more to ADMA or ALLO?

Which has more risk and volatility, ADMA or ALLO?

Which has preferable earnings & valuation, ADMA or ALLO?

Is ADMA or ALLO more profitable?

Summary

How does Allogene Therapeutics compare to Pharvaris?

Do analysts rate ALLO or PHVS?

Which has stronger earnings & valuation, ALLO or PHVS?

Does the media favor ALLO or PHVS?

Do insiders & institutionals believe in ALLO or PHVS?

Which has more risk and volatility, ALLO or PHVS?

Is ALLO or PHVS more profitable?

Summary

How does Allogene Therapeutics compare to Vericel?

Which has more risk and volatility, ALLO or VCEL?

Do analysts prefer ALLO or VCEL?

Is ALLO or VCEL more profitable?

Do institutionals & insiders believe in ALLO or VCEL?

Which has better earnings & valuation, ALLO or VCEL?

Does the media favor ALLO or VCEL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALLO vs. The Competition

Allogene Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools